Opitz I, Lauk O, Meerang M, et al. - Given the assumption of the promising value of intracavitary chemotherapy in improving local tumor control for malignant pleural mesothelioma with reported high morbidity rates, researchers sought to present the results of a phase I trial of intracavitary cisplatin-fibrin after surgical tumor resection. In this trial, treatment was provided to 12 patients (75% International Mesothelioma Interest Group stage III-IV) with 4 dose levels of intracavitary cisplatin-fibrin (11-44 mg/m² body surface area) in a dose-escalating design. They encountered no dose-limiting toxicity. Four patients (33%) experienced major morbidity. No 30-day and 90-day mortality were evident. Overall, the administration of intracavitary cisplatin-fibrin was identified as safe with favorable pharmacokinetics. Although the advanced disease was evident in most patients, comparable long-term outcomes to other multimodal concepts were observed. A confirmation phase II trial is ongoing.